Simeon J. George

San Francisco, USA

Simeon is CEO of SR One. He joined the firm in 2007 and established the San Francisco office in 2010. He previously trained as a physician and worked in management consulting and investment banking. Simeon was formerly a Consultant at Bain & Co. and an Associate in the healthcare investment banking group of Goldman Sachs.


M.D., University of Pennsylvania School of Medicine

M.B.A., The Wharton School of Business, University of Pennsylvania B.A., Neuroscience, Johns Hopkins University

Portfolio Companies

Board Representation: CRISPR Therapeutics (NASDAQ: CRSP), Nkarta (NASDAQ: NKTX), Turning Point Therapeutics (NASDAQ: TPTX), Design Therapeutics, eFFECTOR Therapeutics, Birdrock Bio and Rockend

Prior Board Representation: Principia Biopharma (Acquired by Sanofi), Progyny (NASDAQ: PGNY), Genocea (NASDAQ: GNCA), HTG Molecular (NASDAQ: HTGM), Semprus (Acquired by Teleflex)

Involved with: MiroBio Limited

Rajeev Dadoo

San Francisco, CA, USA

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. Rajeev has previously worked in the Competitive Excellence group within GSK on company-wide strategic and operational projects. Rajeev has also worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, he worked at Genome Therapeutics in business development and was a co-founder of Unimicro Technologies.


MBA, The Wharton School of Business, University of Pennsylvania

Ph.D., Chemistry, Stanford University

B.A., Math and Chemistry, Knox College

Portfolio Companies

Board Representation: Avhana Health, Dren Bio, IlluminOss, Navitor Pharmaceuticals, Nimbus Therapeutics, Palleon Pharmaceuticals, Tranquis Therapeutics

Prior Board Representation: Adheron (acquired by Roche), Concert (NASDAQ: CNCE), Cydex (acquired by Ligand), iPierian (acquired by BMS), NeuroTherapeutics Pharma, Propeller (acquired by ResMed), True North (acquired by Bioverativ)

Matthew Foy

San Francisco, CA, USA

Matthew joined SR One’s London office in 2011. Previously he spent eight years at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York.


Biological Sciences – Molecular biology, Genetics and Statistics – University of Oxford

Corporate Finance – London Business School

Drug Discovery – University College London

Portfolio Companies

Board Representation: AtoxBio, Decibel Therapeutics, NovellusDx, PsiOxus, Pulmocide, Rockend, VHSquared

Prior Board Representation: Atopix, Puridify (acquired by GE)

Involved with: Asceneuron

Jill Carroll

Mid-Atlantic, USA

Jill joined SR One in 2011 with a background in biotech partnering and corporate development. Previously, she completed multiple pharma partnerships and substantial private and public financings at Dynavax Technologies (NASDAQ: DVAX). Jill was formerly a biopharmaceutical industry consultant at Clearview Projects and Mercer Management Consulting.


M.S., Biochemistry, Cellular and Molecular Biology, Johns Hopkins University

B.S., Chemistry, Duke University

Portfolio Companies

Board Representation: Pandion (NASDAQ: PAND), Arcellx, HotSpot Therapeutics

Prior Board Representation: Alios (acquired by JNJ), Nkarta (NASDAQ: NKTX), Tioma Therapeutics

Involved with: AGTC (NASDAQ: AGTC), eFFECTOR, Progyny, Principia Biopharma (NASDAQ: PRNB), 858 (formerly Gotham Therapeutics), Second Genome

Deborah Harland

London, UK

Debbie joined SR One in 2005 to establish the European investment office with a background in drug development and licensing gained through numerous prior roles held in clinical development, medical affairs and business development with Merrell Dow, SmithKline Beecham and GSK. Debbie is also an independent director on the board of Cancer Research Technology, the commercialization arm of Cancer Research UK and a member of the Advisory Board of the University of Cambridge Maxwell Centre’s ‘Impulse’ program for young entrepreneurs.


MBA, Henley Management College

Ph.D., Pharmacology, University of London

B.Sc. (Hons) Pharmacology, University of Bath

Portfolio Companies

Board Representation: Asceneuron, AtoxBio, F-star, MiroBio, Mission Therapeutics, Pulmocide, PsiOxus, VHsquared

Prior Board Representation: 7TM Pharma, Ablynx (EURONEXT:ABLX; acquired by Sanofi), Addex Therapeutics (SIX:ADXN), Atopix Therapeutics (acquired by Chiesi), Bicycle Therapeutics (NASDAQ:BCYC), Pharmakodex, Syntaxin (acquired by Ipsen)

Involved with: Genocea (NASDAQ:GNCA), HotSpot Therapeutics

Rodger Novak


Rodger is a consultant for SR One. He joined the firm in 2020 and works in Switzerland. He is a trained physician and has worked for almost 20 years as senior executive in the industry; more recently as Global Head Anti-Infectives R&D at Sanofi and former CEO and now Chair of the Board of CRISPR Therapeutics. Before his career in pharma he was in academia in leading US research institutions like The Rockefeller University. He became a tenured professor in microbiology at the Vienna Biocenter in 2001.


M.D., Philipps University, Marburg, Germany

Portfolio Companies

Current Board Representation: CRISPR Therapeutics (NASDAQ: CRSP) (Chair), Rockend (Chair)

Eliot Charles

London, UK

Eliot is a Venture Partner with SR One. He joined the firm in 2019 and works in the London office. He is a founder and Executive Chairman at MiroBio and an advisor to Rockend. Eliot started his career at Genentech and later led Amgen’s External R&D Affairs group. He has also been Partner and Venture Partner at Apax Partners and New Leaf Venture Partners, respectively. Eliot was also the founding COO of Prinicipia Biopharma.


Ph.D., Brain and Cognitive Sciences, MIT

M.B.A., University of Chicago, GSB

Portfolio Companies


Heather Behanna

San Francisco, CA, USA

Heather joined SR One in 2019.  Previously, she worked as a Principal at Sofinnova Ventures, and prior to that, as an Equity Research Analyst at two boutique Investment Banks.  Heather was formally a Chemist at the Astellas Research Institute and Adjunct Faculty at Northwestern University.


Ph.D., Chemistry, Northwestern University

MSc., Organic Chemistry, Weizmann Institute of Science

B.S., Biopsychology, Tufts University

Portfolio Companies

Board Representation: Second Genome, Dren Bio (Board Observer)

Involved with: Design Therapeutics, MiroBio

Amit Shah

London, UK

Amit started at S. R. One in January 2018.  Prior to this, he worked in late phase R&D clinical development, global medical affairs, and early pipeline commercial strategy at GSK.  Before joining GSK in March 2016, he practiced as a plastic surgeon for ten years in London, having specialized in head and neck, breast, and perineal cancer reconstruction.


M.D., University of Cambridge, UK

M.A., Neuroscience, University of Cambridge, UK

Portfolio Companies

Current Board Representation: Gladius Pharma, HotSpot Therapeutics (Board Observer), IlluminOss (Board Observer)

Prior Board Representation: CalciMedica

Involved with: Principia Biopharma (NASDAQ:  PRNB), Nkarta (NASDAQ: NKTX), and eFFECTOR Therapeutics

Karen Narolewski Engel

Philadelphia, PA, USA

Karen joined SR One in 2002. She brings a range of experience to SR One, including extensive contract, legal and finance experience gained through various positions held at Quest Diagnostics, SmithKline Beecham Clinical Laboratories, and Shared Medical Systems.


MBA, LaSalle University

B.A., Political Science, Bloomsburg University

Portfolio Companies

Previously involved with: Avhana Health, Scynexis (NASDAQ: SCYX), NuPathe (acquired by Teva Pharmaceuticals) and Rib-X Pharmaceuticals now Melinta Therapeutics (NASDAQ: MLNT)

James Macadam

London, UK

James is Finance Director at SR One based in London. He joined the firm in 2020 having led the financial reporting and spin-out workstreams for SR One over the course of 2019. Previously, James spent 3 years within the GSK Group in roles including finance lead for the Pharma business in Finland and in corporate finance in London.


MBA, HEC Paris

University of Oxford

University of Cambridge

Philip B. Habib

London, UK

Philip joined SR One in 2020 and leads the firm’s Capital Partnering effort. He has more than 12 years of experience in Venture capital, Private equity, and Real Estate.

Philip was formerly in the Business Development (M&A) and the Leveraged Finance groups at General Electric, and began his career as a private equity and venture capital consultant at Cambridge Associates, the leading investment advisory firm.


M.A. Economics, The University of Edinburgh

M.B.A., London Business School

SR One (SR One) respects the privacy of visitors to its websites and is committed to the protection of their personal information. This Privacy Statement explains the data collection, transfer, processing, use, disclosure, and security practices of the ‘’ website (the “Site”).

Note that this Privacy Statement does not apply to information collected from offline resources and communications.

Binding nature

By accessing and using the Site, you agree and consent to the collection, transfer, processing, use and disclosure of your personally identifiable information as outlined in this Privacy Statement.

Description of the information SR One may collect and how it is used

1. Personally Identifiable Information

SR One directly collects personally identifiable information (i.e., information from which you can be identified, such as name, address, telephone number or e-mail address) only when it is asked for and/or you voluntarily submit it to us on this Site. We may use the information to respond to your requests; improve our level of service and the content of our Site; provide you with tips, helpful information, product news and updates; notify you of new SR One products and services (where you have agreed to this); seek your views on our products and services; consider your application for employment; and for our own administrative and quality assurance purposes.

This Site is not intended or designed to attract children under the age of 16. We do not knowingly collect personally identifiable information via this Site from visitors in that age group without the explicit consent of a parent or guardian.

How we protect your personally identifiable information

SR One is committed to using commercially reasonable means to ensure that your personally identifiable information is protected appropriately, and according to the sensitivity of the information. SR One uses a variety of security technologies and procedures to help protect your personally identifiable information from unauthorized access, use, or disclosure. For example, we store the personally identifiable information you provide to SR One on computer servers with limited access that are located in controlled facilities. Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personally identifiable information, we cannot guarantee the security of the personally identifiable information you transmit to our Site; any transmission is at your own risk. While we cannot guarantee that loss, misuse or alteration to data will not occur, once we have received your information, we make commercially reasonable efforts to prevent such unfortunate occurrences.

Sharing personally identifiable information with third parties

SR One will not sell or rent personally identifiable information to third parties. Sometimes selected third parties are however used to provide SR One with support services in connection with the Site and such parties may, from time to time, have access to your information to enable them to provide those services to SR One. Please rest assured that all companies providing such support services are required by SR One to meet the same standards of data protection as SR One and are prohibited from using the information for their own purposes.  In particular, SR One does not allow its service providers to use your personally identifiable information for their own marketing activities.

In certain special cases, we may disclose your personally identifiable information in the following circumstances:

  1. when we have reason to believe that disclosing this information is necessary to identify, contact or bring legal action against someone who may be causing injury to you, or otherwise injuring or interfering with SR One’s rights, property or operations, other users of this Site, or anyone else who could be harmed by such activities;
  2. when we believe the law requires it, or in response to any demand by law enforcement authorities in connection with a criminal investigation, or civil or administrative authorities in connection with a pending civil case or administrative investigation; or
  3. in connection with a substantial corporate transaction, such as the sale of a product line or division, a merger, consolidation, asset sale, or in the unlikely event of bankruptcy.

Personally identifiable information collected on the Site may be transferred to, stored and processed in your country of residence or any other country in which SR One or its affiliates, subcontractors or agents maintain facilities, including the United States and outside the European Economic Area (“EEA”).  You should also note that your information may be processed in countries with lower data protection standards than your country of residence. By using the Site, you consent to any transfer, processing or storing of information outside of your country of residence, and outside the EEA. SR One will ensure that if information is transferred outside your country of residence, it will still be treated in accordance with this Privacy Statement.


You have a right to update or correct your personally identifiable information at any time by contacting us in writing, as specified at the end of this Privacy Statement. You may have the right to access information held about you pursuant to your local laws and can be exercised in accordance with such laws. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

2. Non-Personally Identifiable Information

SR One also automatically collects (where available) information about your browser type and operating system, websites you visited before and after visiting the Site, standard server log information and IP Address (see below).

This information (which does not identify any individual) is aggregated to gather data such as the total number of visits to our Site, the number of visitors to each page of our Site, and the domain names of our visitors’ internet service providers. We use this information, which remains in aggregate form, to understand how our visitors use our Site so that we may improve it and the services we offer. We may also share this aggregated information with other companies within the SR One group and with other third parties. NO PERSONALLY IDENTIFIABLE INFORMATION IS DISCLOSED IN THIS PROCESS.

Use of IP Addresses

An Internet Protocol (IP) address is a set of numbers that is automatically assigned to your computer whenever you log on to your internet service provider or through your organisation’s local area network (LAN) or wide area network (WAN). Web servers automatically identify your computer by the IP address assigned to it during your session online.

SR One, or third party companies acting on behalf of SR One, may collect IP addresses for the purposes of systems administration and to audit the use of our Site. We do not ordinarily link a user’s IP address to information that directly identifies that user, which means each user’s session will be logged, but the user remains anonymous to us. However, we may use IP addresses to identify users of our Site when we feel it is necessary to enforce compliance with the Site’s terms of use, or to protect our service, Site or other users.


This Site may use technology called “cookies”. A cookie is a small text file that is placed on your hard disk by a Web page server. Cookies help provide additional functionality to the Site or help us analyse usage of the Site more accurately. For instance, our server may set a cookie that keeps you from having to enter a password more than once during a visit to the Site. In all cases in which cookies are used, we will not collect information that directly identifies you. The only personally identifiable information SR One collects directly is the information you voluntarily provide.

You have the ability to accept or decline cookies. Most Web Browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies, or receive a warning before a cookie is stored, if you prefer. Please refer to your Internet Browser’s instructions or help screen to learn more about these functions and to specify your cookie preferences. If you choose to decline cookies, you may not be able to fully experience the interactive features of this Site or any other websites that you visit.If you wish to disable the Site’s ability to passively collect information about your website interactions as described in Section 2 above, you have the ability to opt out of such collection. Go to this link and follow the Opt-Out Policy Instructions. The opt-out process will require that you permit the placement of a cookie on your computer that indicates that you do not wish that we automatically collect information about your website interactions. In the event you remove your cookies from your computer or if you change computers or Web browsers, such collection will automatically resume.

Links to other web sites

This Site may from time to time provide links to other GlaxoSmithKline, SR One and third party websites as a service to our users. This Privacy Statement does not apply to those websites. You agree that, if you choose to enter such a linked site, that SR One is not responsible for the availability of such websites and does not review or endorse and shall not be liable, directly or indirectly, for (i) how these websites treat your personally identifiable information, (ii) the content of such websites, including (without limitation) any advertising, products, goods or other materials or services available from such websites and (iii) the use that others make of these websites.

Please ensure that you check the legal and privacy statement posted on each website you link to before entering any personally identifiable information.


We may occasionally update this Privacy Statement. If the changes we make are material, we also may post a notice on this Site. We encourage you to periodically review this Privacy Statement to stay informed about how we are helping to protect the personally identifiable information we collect. Your continued use of the Site constitutes your agreement to the Privacy Statement and any updates.

Contact us

Questions, comments and requests regarding this Privacy Statement are welcomed and should be addressed to:

SR One, 161 Washington Street, Suite 500, Conshohocken, PA  19428, USA.

This Web Site has been developed as a service of SR One. Like any other service, in spite of our best efforts the information in this Web Site may become out of date over time.

Nothing on this Web Site should be construed as the giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important that you rely only on the advice of a health care professional to advise you on your specific situation.

SR One accepts no liability for the accuracy or completeness or use of, nor any liability to update, the information contained on this Web Site. These materials are provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusion may not apply to you.

This U.K. – based Web Site may link you to other Web Sites on the Internet, including the Web Sites for GlaxoSmithKline and SR One affiliates in other countries. SR One cannot take responsibility for information found on third party Web sites outside its control. While SR One attempts to provide links only to third-party Web Sites that comply with all applicable laws and regulations and SR One’s standards, please understand that the content on these third-party Web Sites is subject to change without notice to SR One. We therefore cannot be responsible for, and accept no liability for, any information or opinion contained in any third-party Web Site.

Nothing on this website constitutes an invitation or offer to invest or deal in the securities or ADRs of GlaxoSmithKline or of any entity described or listed on this Web Site. In particular, actual results and developments may be materially different from any forecast, opinion or expectation expressed on this Web Site and the past performance of the price of securities must not be relied on as a guide to their future performance.

Copyright and intellectual property

SR One hereby authorizes you to copy materials published by it on this Web site for non-commercial use only, provided any copy of these materials which you make shall retain all copyright and other proprietary notices and any disclaimer contained thereon and on this Web Site.

Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent or trademark of SR One or any third party. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any SR One copyright.

Trademarks and service marks owned by or licensed to SR One are presented as italicised typefaces. British and American spellings are used, depending on the author or source of the information. SR One claims no ownership in, nor any affiliation with, any third-party trademarks appearing in this Web Site. Such third-party trademarks are used only to identify the products and services of their respective owners, and no sponsorship or endorsement on the part of SR One should be inferred from the use of these marks.

Should any viewer of a SR One published document respond with information including feedback data such as questions, comments, suggestions, or the like regarding the content of any such SR One material, such information shall be deemed to be non-confidential and we shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation.

We shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing and marketing products incorporating such information.